Yumanity Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch YMTX and buy or sell other stocks, ETFs, and their options commission-free!

About YMTX

Kineta, Inc. is a clinical-stage biotechnology company, which engages in the development of immunotherapies for cancer patients. Its pipeline includes immuno-suppression: aVISTA mAb and exhausted T-cells: aCD27 agonist mAb. 

CEO
Shawn P. Iadonato, PhD
CEOShawn P. Iadonato, PhD
Employees
5
Employees5
Headquarters
Mercer Island, Washington
HeadquartersMercer Island, Washington
Founded
2008
Founded2008
Employees
5
Employees5

YMTX Key Statistics

Market cap
34.53M
Market cap34.53M
Price-Earnings ratio
-0.50
Price-Earnings ratio-0.50
Dividend yield
Dividend yield
Average volume
15.46K
Average volume15.46K
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$1.15
52 Week high$1.15
52 Week low
$0.1806
52 Week low$0.1806

Stock Snapshot

With a market cap of 34.53M, Yumanity Therapeutics(YMTX) trades at $2.55. The stock has a price-to-earnings ratio of -0.50.

Yumanity Therapeutics(YMTX) stock opened on 2025-12-29 at —. The price climbed to — and dipped to —.

Yumanity Therapeutics(YMTX) shares are trading with a volume of 0, against a daily average of 15.46K.

In the last year, Yumanity Therapeutics(YMTX) shares hit a 52-week high of $1.15 and a 52-week low of $0.18.

In the last year, Yumanity Therapeutics(YMTX) shares hit a 52-week high of $1.15 and a 52-week low of $0.18.

People also own

Based on the portfolios of people who own YMTX. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.